Physician profile

Robert Dons

Endocrinology, Diabetes & Metabolism · Chicago, IL

NPI 1508905928

$413.81

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$47.79

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $239.24 2020
Sanofi-Aventis U.S. LLC $61.34 2020-2023
Lilly USA, LLC $27.90 2020-2024 Jardiance
Ultragenyx Pharmaceutical INC. $20.50 2019
Abbvie INC. $18.67 2020
Abbott Laboratories $17.01 2020
Medtronic Minimed, INC. $16.06 2020
Medtronic, INC. $13.09 2024 Minimed 780g

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert Dons

$413.81

in general payments reported 2019-2025

Years
2019-2024
Top company
Astrazeneca Pharmaceuticals Lp

https://glasscript.com/doctor/204143/robert-dons

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.